V-016
烟酰胺 (维生素B3)标准液 CRM 溶液
1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
别名:
烟酰胺, 维生素 B3, 吡啶-3-甲酰胺, 烟碱酰胺, 维生素 PP
等级
certified reference material
质量水平
表单
liquid
特点
Snap-N-Spike®/Snap-N-Shoot®
包装
ampule of 1 mL
制造商/商品名称
Cerilliant®
浓度
1.0 mg/mL in methanol
技术
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
mp
128-131 °C (lit.)
应用
clinical testing
clinical testing
包装形式
single component solution
储存温度
−20°C
SMILES字符串
NC(=O)c1cccnc1
InChI
1S/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9)
InChI key
DFPAKSUCGFBDDF-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
一般描述
烟酰胺也称为烟碱酰胺或尼古丁酰胺。它是植物和动物食物中维生素B3的水溶性形式，并主要用作膳食补充剂。
应用
认证加标溶液适用于多种测试应用，包括通过 HPLC 对药物制剂或膳食补充剂进行的质量控制测试。
烟酰胺可作为分析参考标准品，用于通过经电喷雾质谱确证的平面色谱多重检测对功能饮料中的分析物、通过紫外-可见分光光度法和多元分析对药物制剂中的分析物进行测定。
烟酰胺可作为分析参考标准品，用于通过经电喷雾质谱确证的平面色谱多重检测对功能饮料中的分析物、通过紫外-可见分光光度法和多元分析对药物制剂中的分析物进行测定。
生化/生理作用
烟酰胺是维生素B3的酰胺衍生物，是PARP抑制剂
法律信息
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
警示用语：
Danger
危险分类
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
靶器官
Eyes
储存分类代码
3 - Flammable liquids
WGK
WGK 2
闪点(°F)
49.5 °F - closed cup
闪点(°C)
9.7 °C - closed cup
法规信息
危险化学品
此项目有
Simultaneous determination of riboflavin, pyridoxine, nicotinamide, caffeine and taurine in energy drinks by planar chromatography-multiple detection with confirmation by electrospray ionization mass spectrometry
Aranda M and Morlock G
Journal of Chromatography A, 1131(1-2), 253-260 (2006)
Simultaneous determination and classification of riboflavin, thiamine, nicotinamide and pyridoxine in pharmaceutical formulations, by UV-visible spectrophotometry and multivariate analysis
Lopez-de-Alba LP, et al.
Journal of the Brazilian Chemical Society, 17(4), 715-722 (2006)
Takeshi Natori et al.
Gan to kagaku ryoho. Cancer & chemotherapy, 40(5), 635-637 (2013-07-19)
Sorafenib is an oral multi-kinase inhibitor that targets tumor growth and angiogenesis signal transduction pathways. Two global phase III trials showed that sorafenib prolonged the survival of patients with advanced hepatocellular carcinoma (HCC). Based on the positive results of these
Is India ready to lead the battle for fair access to medicines?
Lancet Oncology
The Lancet. Oncology, 14(6), 437-437 (2013-05-04)
Case of sorafenib-induced thyroid storm.
Sigurdis Haraldsdottir et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(16), e262-e264 (2013-04-24)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持